New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
09:16 EDTDISH, ENDP, NQ, SPPI, ARNA, GTAT, CASI, BDSIOn The Fly: Pre-market Movers
HIGHER: DISH (DISH), up 2.4% following positive mention in this weekend's Barron's, contending the shares could climb 20%... BioDelivery Sciences (BDSI), up 15% after announcing results from its Endo buprenorphine trial with an Endo (ENDP) division... CASI Pharmaceuticals (CASI), up 3.7% after confirming that it received FDA orphan drug designation for a drug... Spectrum (SPPI), up 3% after being granted accelerated approval for Beleodaq from FDA. LOWER: GT Advanced (GTAT), down 10% after downgraded at UBS and Cannaccord... NQ Mobile (NQ), down 3.5% after Muddy Waters says the company has likely already decided to fire PwC... Arena Pharmaceuticals (ARNA), down 3% after Chairman, President and CEO Jack Lief sold 223,525 shares of the company's common stock pursuant to a Rule 10b5-1 trading plan on July 1, according to a regulatory filing from late Thursday.
News For DISH;GTAT;NQ;BDSI;ARNA;ENDP;CASI;SPPI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 23, 2015
08:44 EDTSPPIRoth Capital downgraded Spectrum on court case loss
Subscribe for More Information
07:31 EDTENDP, BDSIEndo, BioDelivery Sciences announce acceptance of NDA for Belbuca
Subscribe for More Information
07:16 EDTSPPISpectrum pullback a 'table-pounding' buying opportunity, says H.C. Wainwright
H.C. Wainwright calls the sell-off in shares of Spectrum Pharmaceuticals (SPPI) after a District Court in Nevada ruled that the levoleucovorin formulation used by Sandoz does not infringe the company's Fusilev intellectual property as a "table-pounding" buying opportunity. The firm reminds investors that Fusilev is still protected by orphan drug exclusivity until 2018 as a treatment for patients with colorectal cancer. It keeps a Buy rating on Spectrum with a $15 price target.
07:14 EDTSPPISpectrum says plans to appeal patent suit loss to Novartis unit
Spectrum Pharmaceuticals (SPPI) confirmed in a regulatory filing that on February 20, the U.S. District Court for the District of Nevada ordered that judgment be entered in favor of defendant Sandoz in the matter entitled Spectrum Pharmaceuticals, Inc. et al v. Sandoz Inc. "Spectrum Pharmaceuticals Inc. intends to appeal this decision and the ultimate outcome of this litigation remains uncertain," the company stated. Sandoz is the generic pharmaceuticals division of Novartis (NVS).
06:08 EDTDISHDISH reports 2.6M activations of gorss new PAy-TV subscribers
Subscribe for More Information
06:08 EDTSPPISpectrum downgraded to Neutral from Buy at Roth Capital
06:07 EDTDISHDISH reports FY14 EPS $2.04, consensus $1.59
Reports FY14 revenue $14.6B, consensus $14.66B
06:06 EDTDISHDISH announces President and CEO Joseph Clayton to retire March 31, 2015
Subscribe for More Information
February 22, 2015
15:59 EDTENDPValeant to buy Salix for $10.1B, FT says
Subscribe for More Information
February 20, 2015
17:48 EDTSPPISpectrum awards 2014 cash performance awards to C-level executives
On February 18, the compensation committee of the board of Spectrum Pharmaceuticals determined that the company materially accomplished substantially all major goals established at the outset of 2014. Based on an assessment of the company’s performance, the committee determined cash performance awards for its CEO, Rajesh Shrotriya, who got a salary increase of 5.0% and a $900,000 cash bonus; its COO, Joseph Turgeon, who got a 4.5% raise and a $330,000 bonus; its CFO, Kurt A. Gustafson, who got a 4.4% raise and a $225,000 bonus; and its Chief Medical Officer, Lee F. Allen, who got a 3.4% raise and a $270,000 bonus. The Fly notes that Spectrum's stock is down 30% in after-hours trading after a Bloomberg report that the company had its Fusilev patent ruled invalid by a Nevada court.
16:37 EDTSPPISpectrum down 34% after Fusilev patent reportedly ruled invalid
Subscribe for More Information
16:36 EDTSPPISpectrum Fusilev patent ruled invalid by court, Bloomberg reports
13:56 EDTDISHAT&T VP critical of Dish auction tactics
AT&T (T) VP of Federal Regulatory Joan Marsh stated in a post to a corporate blog that FCC Auction 97 represents "hard evidence that there is significant continuing interest in licensed spectrum... It didn't matter that it was mid-band spectrum. It mattered only that it was broadband spectrum." Marsh notes that Dish (DISH) won more licenses than any other bidder though "none of that spectrum is currently supporting commercial wireless services," with her suggestion being that "auctions should be designed to ensure that licenses go to those willing to deploy networks – not speculators or stockpilers...The government should continue to place a high priority on allocating new licensed bands to the wireless industry." Marsh continues her analysis of Dish, claiming the double and triple-bidding activity carried out by its two designated entities "circumvented auction activity rules, masked actual demand and distorted the auction," as they were able to win significant allocations while enjoying a 25% small business discount. In response to Dish claims that all companies use DEs, Marsh replies that "in more recent auctions... bidders like AT&T, Verizon (VZ) and T-Mobile (TMUS) had no DE relationships, participated directly and paid full price for their licenses." Reference Link
09:17 EDTENDPEndo price target raised to $101 from $86 at Goldman
Subscribe for More Information
08:21 EDTBDSI, ENDPSummer Street still feels Endo could acquire BioDelivery Sciences
Summer Street reiterated its belief that Endo (ENDP) could acquire BioDelivery Sciences (BDSI), its partner on multiple products. The firm says scripts for BioDelivery's Bunavail continue to trend in the right direction. It reiterates a Buy rating on the stock with a $25 price target.
February 19, 2015
16:34 EDTENDPAmerican Medical Systems enrolls 1,000th patient in PROPPER registry
American Medical Systems, or AMS, a subsidiary of Endo International, announced the enrollment of the 1,000th patient in the largest prospective, multi-year, global registry study of penile prosthetic outcomes in the world. The study, entitled PROPPER, or Prospective Registry of Outcomes with Penile Prosthesis for Erectile Restoration, is sponsored by AMS and is being conducted by a team of experienced urologists at 11 North American sites. It aims to better characterize real-world patient satisfaction and other outcomes among men who are receiving prosthetic implants to treat their erectile dysfunction. All patients enrolled in the registry will be implanted with penile implants manufactured by AMS, the majority of whom will receive the three piece inflatable penile prosthesis, the AMS 700.
06:13 EDTENDPEndo resumed with a Buy at Citigroup
Price target raised to $98 from $87.
February 17, 2015
17:02 EDTENDPSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
11:14 EDTNQBlock sees 'pure speculation' as only reason investors hold NQ Mobile stock
Subscribe for More Information
06:15 EDTDISHCiti sees three options for DISH, including sale to Verizon
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use